Related Experiment Video

Updated: May 31, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs

Justin Hean1, Carol Crowther, Abdullah Ely

  • 1Antiviral Gene Therapy Research Unit; School of Pathology; University of the Witwatersrand Medical School; South Africa.

Artificial DNA, PNA & XNA
|June 21, 2011
PubMed

Insights

New altritol-containing synthetic siRNAs (ANA siRNAs) effectively silence hepatitis B virus (HBV) replication in vivo. This novel RNA interference therapy shows promise for treating chronic HBV infection with reduced side effects.

Area of Science:

  • Hepatology
  • Virology
  • Molecular Therapy

Background:

  • Chronic hepatitis B virus (HBV) infection affects 6% of the global population, posing a significant risk for hepatocellular carcinoma.
  • Current treatments for chronic HBV infection have limited efficacy, highlighting the need for novel therapeutic strategies.
  • RNA interference (RNAi) offers a promising approach to silence HBV gene expression, but requires further technological refinement for clinical application.

Purpose of the Study:

  • To evaluate the efficacy and safety of altritol-containing synthetic siRNAs (ANA siRNAs) for silencing HBV replication in vivo.
  • To assess the potential of ANA siRNAs, delivered as lipoplexes, to overcome limitations of current RNAi-based HBV therapies.
  • To investigate the impact of ANA modification on off-target effects and immunostimulation associated with siRNA therapy.

Main Methods:

  • Utilized a stringent HBV transgenic mouse model to test ANA siRNAs administered as lipoplexes.
  • Assessed the in vivo silencing of HBV replication and evaluated potential toxicity.
  • Compared the immunostimulatory effects of ANA siRNAs with unmodified siRNAs.

Main Results:

  • ANA siRNAs demonstrated significant in vivo silencing of HBV replication.
  • Approximately 50% inhibition of HBV replication was achieved without observable toxicity.
  • ANA modification significantly attenuated non-specific immunostimulation observed with unmodified siRNAs.

Conclusions:

  • ANA siRNAs represent a promising therapeutic strategy for silencing HBV replication in vivo.
  • ANA modification of siRNAs can reduce undesirable immunostimulatory side effects, enhancing their safety profile.
  • ANA siRNA therapeutic lipoplexes show potential for future clinical application in treating chronic HBV infection.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...